中国经济网11月13日讯（记者王婉莹）11月12日，第十八届中国－欧盟投资贸易科技合作洽谈会（简 称"欧洽会"）新闻发布会在北京举行。本届欧洽会将于11月19日至21日在成都举办，以"互信互通·共享 共赢"为主题，围绕中欧双边经贸关系、产业链供应链合作等话题展开交流研讨。 自创办以来，欧洽会累计吸引1.2万多家中欧企业踊跃参与，成功安排企业配对洽谈逾2.9万场次，达成 意向性合作协议超过3200项。中国欧盟商会副主席冉梦之表示："当创新者相聚，必将创造非凡。2025 年将迎来中欧建交50周年，使本届会议更具特殊意义。" 冉梦之指出，成都与四川不仅是中国西部的门户，更日益成为具有全国乃至全球影响力的创新枢纽，未 来正在这里被共同塑造。 本次会议预计参会人数超过600人，已有来自20多个国家（地区）的600余名嘉宾确认出席，包括多国驻 华使领馆代表、20家重要商协会，以及三峡集团、宁德时代（300750）、阿斯利康、拜耳等高能级国际 企业。西班牙纳瓦拉大区主席、瑞士达沃斯副市长等也将率团参会，共商中欧城市合作新机遇。 会议聚焦前沿产业，围绕中欧产业互补性和全球发展趋势，结合成都产业优势，设置了能源环保、生物 医药 ...

Core Insights - The 18th China-EU Investment Trade and Technology Cooperation Fair (EU Fair) is set to take place from November 19 to 21 in Chengdu, focusing on enhancing cooperation in trade, investment, and technology between China and the EU [1][2]. Group 1: Event Overview - The EU Fair has evolved into one of the largest platforms for China-EU economic and technological cooperation, with participation from over 1,200 companies and more than 29,000 business matching sessions since its inception in 2002 [1]. - The event is expected to attract over 600 attendees from the business and academic sectors of both China and Europe, including representatives from 19 European countries and major companies like Three Gorges Group, CATL, and AstraZeneca [1]. Group 2: Themes and Focus Areas - The theme of this year's fair is "Mutual Trust and Shared Benefits," emphasizing the economic complementarity and responsibilities of both parties in a rapidly changing world [2]. - The fair will feature five parallel industry matchmaking sessions focusing on energy and environmental protection, biomedicine, digital culture and creativity, agricultural products, and intelligent robotics [4][5]. Group 3: Economic Context - In the first ten months of this year, the total value of goods trade between China and the EU reached $680.17 billion, with a year-on-year growth rate of 4% [6]. - Both parties are committed to deepening mutually beneficial cooperation and exploring various economic agreements, including investment treaties, to enhance trade and investment liberalization [6].

Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

Core Viewpoint - AstraZeneca's stock price reached a historic high of £134.6, driven by strong Q3 earnings and a favorable U.S. drug pricing agreement, boosting market confidence and contributing to the rise of the FTSE 100 index [1][3][7]. Group 1: Stock Performance - On November 11, AstraZeneca's stock price increased by 2.5% to £134.6, marking a historic high and solidifying its position as the largest weight in the FTSE 100 index [3][5]. - The company's market capitalization approached £210 billion (approximately $282 billion), reinforcing its status as the leading stock in the UK market [3]. Group 2: Financial Performance - AstraZeneca reported a Q3 revenue growth of 11% year-over-year and a core earnings per share increase of 15%, with all business segments and key regional markets showing robust growth [7]. - The strong performance was primarily driven by sustained demand for innovative drugs [7]. Group 3: Market Factors - The recent U.S. drug pricing agreement reached in October alleviated market concerns regarding U.S. pharmaceutical policy uncertainty, providing additional support for AstraZeneca's stock price [7]. - The U.S. market, contributing over 40% of AstraZeneca's total sales, plays a significant role in influencing the company's stock performance [7].

Core Viewpoint - AstraZeneca's stock price reached a historic high of £134.6, with a market capitalization nearing £210 billion ($282 billion), solidifying its position as the largest weight in the FTSE 100 index [1]. Group 1: Stock Performance - AstraZeneca's strong performance significantly boosted the FTSE 100 index, which rose by 1.1% to also reach a historic high, driven by improved UK employment data and expectations of interest rate cuts by the central bank [2]. - The stock price increase of AstraZeneca by 2.5% during intraday trading reflects investor confidence and market optimism [1]. Group 2: Financial Results - The recent stock surge is primarily supported by AstraZeneca's better-than-expected earnings report, which showed an 11% year-over-year increase in total revenue for the first three quarters, and a 15% growth in core earnings per share [4]. - All business segments and major regional markets of AstraZeneca demonstrated robust growth, indicating a strong operational performance [4]. Group 3: Market Environment - The recent agreement on drug pricing in the U.S. has alleviated market concerns regarding uncertainties in U.S. pharmaceutical policies, providing additional support for AstraZeneca's stock price [4]. - The U.S. market, contributing over 40% of AstraZeneca's total sales, plays a crucial role in the company's revenue generation and stock performance [4].

Financing Overview - A total of 19 financing events occurred in Shanghai this week, with 9 disclosing amounts totaling approximately 825.5 million yuan [3][6] - The number of financing events increased by 2 compared to the previous week, which had 17 events [3] - The majority of financing events took place in the Pudong New Area, with 8 events totaling 435 million yuan, followed by Minhang District with 6 events [3] Company Dynamics - Times Technology completed a 300 million yuan B++ round of financing on November 7, with investments from Huaying Capital, Junshan Capital, and PwC Capital [12][13] - Weitao Bio secured over 100 million yuan in angel round financing on November 5, led by Qiming Venture Partners, with participation from B Capital, Shunxi Fund, and Xingze Capital [14][15] - Juyue Testing completed nearly 100 million yuan in A+ round financing on November 6, led by Dongfang Jiafu, with participation from Guoxin Hongsheng and Tianbao Investment [16][17] - Yuesai Biotechnology completed nearly 100 million yuan in strategic financing on November 6, with investments from Shanghai Guotou Xiandao and Pudong Investment Holdings [18][19] Industry Focus - The healthcare sector saw the most financing events this week, with 5 occurrences, followed by integrated circuits with 4 [9][20] - The biopharmaceutical industry is a key focus in Shanghai, highlighted by the recent China International Import Expo where major companies showcased innovative products [20][21] - The Shanghai government has implemented policies to support the development of high-end medical devices, emphasizing the need for advancements in AI medical devices and diagnostic equipment [21]

据主办方介绍，2025可持续全球领导者大会江苏专场不仅是江苏经济与全球可持续发展理念的对话 平台，也是无锡产业与全球资源链接的战略节点。 以此次大会为契机，无锡将充分发挥私募股权投资在服务科技创新、培育发展新质生产力中的重要 作用，依托坚实的产业基础和优质的营商环境，充分拓展与会方在产业、创新、可持续发展等方面合作 空间，以发展"含绿量"做大产业"含金量"，推动科技创新和产业创新融合发展。 大会现场，国联集团生态联盟正式启动，无锡产业招商地图发布。联盟汇聚包括华为、阿斯利康、 中金资本等在内的全球顶尖企业与机构，旨在共同打造"资本驱动、产业协同、服务赋能"的协同生态体 系，为未来创新发展注入最强动能。 开幕式上同步进行了项目签约和基金签约。2025年国联集团完成投资项目394个，投资总规模620亿 元，重点覆盖生物医药、集成电路、先进制造、双碳节能、人工智能等领域，合作新设基金89支，基金 总规模342亿元，招引28个项目落地无锡，投资总规模达178亿元。 日前，2025可持续全球领导者大会江苏专场、第二届国联投资人大会在江苏无锡举办。大会以"锡 引全球资本，赋能现代产业"为主题，集中展示江苏及无锡在可持续发 ...

Core Insights - The 8th China International Import Expo (CIIE) showcases China's commitment to high-level opening up and economic growth, with significant participation from global enterprises [1][6] - The event has attracted a record number of foreign exhibitors and exhibition space, indicating a robust international interest in the Chinese market [2][3] Economic Growth and Market Potential - China's retail sales are projected to exceed 48 trillion yuan in 2024, with expectations to surpass 50 trillion yuan this year, highlighting the growing domestic demand [3] - From 2021 to 2024, domestic consumption is expected to contribute an average of 86.8% to China's economic growth, with final consumption expenditure accounting for 59.9% [3] Innovation and Industry Upgrades - The expo serves as a platform for global companies to align their innovations with China's industrial upgrade needs, presenting opportunities in green transformation and collaborative ventures [4] - Major companies like AstraZeneca and Fosun Pharma are showcasing new products and investments, reflecting the increasing integration of global innovation in the Chinese market [4] Open Market and Global Cooperation - The CIIE emphasizes China's ongoing commitment to openness, with a focus on reducing foreign investment restrictions and expanding service sector access [6] - The event highlights the positive impact of international trade on local economies, as seen with products from countries like Rwanda and Afghanistan contributing to job creation and income [6]

Core Insights - The integration of AI in the medical and pharmaceutical sectors is becoming increasingly prominent, with numerous innovative products showcased at the China International Import Expo, highlighting AI's role in drug development, clinical efficiency, and decision-making [1][2][6]. Group 1: AI Empowerment in Medical Research and Drug Development - The Chinese government has implemented policies to promote AI in the pharmaceutical industry, emphasizing the use of new information technologies in drug research [2]. - Major multinational companies like Roche, AstraZeneca, Johnson & Johnson, and Siemens Healthineers are collaborating with AI firms to advance various projects [2][3]. - Roche's AI-driven solutions, such as the "MDT Intelligent Body" and "Little Roche Smart Star," aim to enhance clinical practice efficiency and support the entire research process, having already assisted over 4,000 doctors in completing more than 600 research projects [3]. Group 2: AI in Medical Devices and Diagnostics - The introduction of AI-powered medical devices is transforming traditional healthcare practices, with companies like Medtronic showcasing their AiBLE smart ecosystem that integrates surgical robots and imaging systems [6]. - Siemens Healthineers presented its AI-driven innovations, including a prostate cancer diagnostic software that enhances detection accuracy and reduces misdiagnosis risks [7]. - Boston Scientific debuted several AI-enabled cardiac health innovations, including the FDA-approved HeartLogic heart failure monitoring system, which can predict heart failure risks [7]. Group 3: Brain-Computer Interface Technology - Brain-computer interface (BCI) technology is emerging as a revolutionary treatment paradigm, enabling patients with severe disabilities to control devices through thought [11][12]. - Siemens Healthineers introduced a comprehensive BCI solution that covers preoperative planning, intraoperative navigation, and postoperative evaluation, facilitating the clinical application of BCI technology [12]. - Medtronic showcased a rechargeable, perceptive closed-loop brain stimulator that offers personalized treatment for conditions like Parkinson's disease, enhancing patient care [12].

Core Insights - The event showcased the sustainable development achievements of Jiangsu and Wuxi, emphasizing collaboration among financial institutions, industry leaders, investors, and experts in the field of sustainability [1] - The conference served as a platform to deepen cooperation between Wuxi and domestic and international investors, with the launch of the Guolian Group Ecological Alliance and multiple project signings [1] Investment and Economic Development - Wuxi has attracted 394 investment projects with a total investment scale of 62 billion yuan, focusing on sectors such as biomedicine, integrated circuits, advanced manufacturing, carbon neutrality, and artificial intelligence [2] - The city has established 89 new funds with a total scale of 34.2 billion yuan, successfully attracting 28 projects with an investment scale of 17.8 billion yuan [2] - Wuxi's industrial foundation includes seven industrial clusters with revenues exceeding 200 billion yuan, five of which are national-level advanced manufacturing clusters [2] Capital Market and Investment Environment - Wuxi has over 120 listed companies on the A-share market and a total scale of private equity funds reaching 85 billion USD, ranking among the top ten in China for equity investment activity [2] - The city is enhancing its multi-layered capital market service system and fostering a diversified venture capital development environment [2] Global Trade and Investment Climate - Wuxi's trade partners span 220 countries and regions, with over 7,200 foreign-funded enterprises and 118 Fortune 500 companies investing in the city [3] - The city has implemented ten measures to facilitate the entry of foreign nationals, including a 240-hour visa-free transit policy at the airport [3] Collaborative Ecosystem - The Guolian Group Ecological Alliance, which includes top global companies and institutions, aims to create a collaborative ecosystem driven by capital, industry synergy, and service empowerment [4] - The alliance is expected to inject strong momentum into Wuxi's future innovation and development [4] Focus on Sustainable Development - The conference emphasized the importance of building a cooperative ecosystem focused on new investments, green initiatives, and digital upgrades to foster sustainable high-quality development [5] - The Guolian Group plays a crucial role in linking various parties in Wuxi's industrial transformation and upgrading process [6] Guolian Group's Achievements - Guolian Group has developed into a local state-owned enterprise with total assets exceeding 330 billion yuan, managing financial assets totaling 2.2 trillion yuan and a fund scale surpassing 280 billion yuan [7] - The group aims to enhance its financial services, strengthen its industrial operations, and deepen its investment strategies to become a leading comprehensive local state-owned enterprise in China [7]